RegeneRx Biopharmaceuticals, Inc. (OTCPK: RGRX)
Health Care · Biotechnology · US
$0.00
-99.60% today · +250.0% 1Y
RegeneRx Biopharmaceuticals, Inc. (OTCPK: RGRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.06K and employs 2 people.
Over the last twelve months the share price has gained 250.0%, trading between 0.00 and 0.17.
Tweenvest scores RegeneRx Biopharmaceuticals, Inc. across four factors: quality 11/100, value 43/100, growth 0/100. Its strongest factor is value.
RGRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.06K
- Revenue (TTM)
- $76.76K
- P/E
- —
- EPS
- -1.18
- Dividend yield
- —
- Beta (5Y)
- 173.81
- 52-week high
- $0.17
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.51M
- Employees
- 2
- Next earnings
- —
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.
- ISIN
- US75886X3061
- Founded
- 1982
- Listed since
- Oct 7, 2003
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.14 | +0.45% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.50 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.69 | +0.39% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.14 | +0.01% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.01 | -1.42% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.